



Non-tuberculous mycobacterial infections—A neglected and emerging problem



Imran Ahmed^a, Simon Tiberi^{b,c}, Joveria Farooqi^a, Kauser Jabeen^a,
Dorothy Yeboah-Manu^d, Giovanni Battista Migliori^{b,c,e}, Rumina Hasan^{a,f,*}

^a Department of Pathology and Laboratory Medicine, Aga Khan University, Karachi, Pakistan

^b Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

^c Department of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK

^d Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana

^e Istituti Clinici Scientifici Maugeri, Tradate, Italy

^f Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK

ARTICLE INFO

Article history:

Received 14 January 2020

Received in revised form 12 February 2020

Accepted 12 February 2020

Keywords:

Non-tuberculous mycobacteria

Diagnosis

Epidemiology

Tuberculosis endemic regions

ABSTRACT

Non-tuberculous mycobacteria (NTM) are ubiquitous dwellers of environmental niches and are an established cause of natural and nosocomial infections. The incidence of NTM infections is rising owing to a growing population of immunocompromised and vulnerable individuals, complex medical and surgical procedures, as well as increased awareness and diagnostic capabilities. The prevalence of different NTM varies between continents, regions, and countries. The true global burden of pulmonary and extrapulmonary disease is unknown and estimates are subject to under and/or over-estimation. Diagnosis requires confirmation by isolation of NTM along with clinical and radiological criteria, which may be suboptimal at all levels. Susceptibility testing is complex and clinical breakpoints are not available for many of the drugs. Frequently, NTM infections are not considered until late in the course of disease. Improved and rapid detection of tuberculosis cases in high-burden countries has, however, also brought NTM infections into the limelight, and has identified a need for research efforts towards rapid diagnostic tests and the identification of biomarkers to monitor the treatment response in patients with NTM infections.

© 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Non-tuberculous mycobacteria (NTM) are ubiquitous and widely found in water and soil, as well as residential environments. Survival in these ecological niches is supported by their ability to form biofilms (Esteban and Garcia-Coca, 2017). Until recently, NTM were considered transient colonizers in humans, although their association with disease is now well recognized and accepted as a growing problem (Prevots et al., 2017). The rise in NTM infections is likely to be multifactorial, including a growing cohort of at-risk populations coupled with perpetually improving diagnostic capacities.

More than 170 species of NTM are currently recognized, with the list ever growing (Forbes, 2017). NTM taxonomy is crowded and complicated, and different species may be more prevalent in

specific geographic settings or milieus (Hoefsloot et al., 2013). NTM may cause pulmonary (nodular and fibrocavitary disease) as well as extrapulmonary disease (cutaneous, bone, disseminated), and frequently affect patients with predisposing conditions, e.g., cystic fibrosis (CF) and bronchiectasis/chronic obstructive pulmonary disease (COPD), as well as people living with HIV (Faverio et al., 2016).

Repeated exposure to environments inhabited by NTM is an accepted mode of transmission (Honda et al., 2018). Infection is frequently acquired through inhalation (i.e., aerosol, showers) or inoculation (trauma, plastic surgery, acupuncture). Outbreaks due to NTM are also well reported in the literature (Buser et al., 2019; Lyman et al., 2017).

Defining the problem

The global burden of NTM disease is largely unknown. Currently, the majority of NTM diseases are not notifiable, notable exceptions being *Mycobacterium chimaera* related to cardiac surgery and heater cooler units and *Mycobacterium ulcerans*. There

* Corresponding author at: Department of Pathology and Laboratory Medicine, Aga Khan University Hospital, Stadium Road, Karachi 74800, Pakistan.
E-mail address: rumina.hasan@aku.edu (R. Hasan).

are several challenges in describing the morbidity and mortality of NTM disease, its incidence and prevalence, trends, and the distribution of infections regionally, nationally, or globally. Moreover, certain countries may be able to enumerate NTM pulmonary cases through their tuberculosis (TB) programmes, but these will be an underestimate as they may only be cases denotified from TB registries, whereas those not presenting to TB clinics may not be captured (Shah et al., 2016).

The classification of NTM disease is an integrated clinical–radiological–microbiological diagnosis, requiring the isolation of the same species of NTM from two separate sputa (or once only from bronchoalveolar fluid), evidence of clinical symptoms, and radiological signs of cavitary or nodular disease on X-ray or computed tomography (Griffith et al., 2007). Laboratory notifications on their own are not able to differentiate true disease from temporary colonization, and other approaches are needed to capture the full burden of NTM disease.

Given the situation, our current knowledge of NTM disease is based on fragments of information from different countries, regions, and multicentre laboratory studies. These suggest that NTM infections are becoming more prevalent; we do not however know whether this is due to our rapidly ageing populations, increasing prevalence of chronic lung diseases, cystic fibrosis cohorts, immunosuppressed patients, or to improved diagnostic methods, or most likely, a combination of these.

Diagnostic challenges

A major obstacle in determining the true burden of disease and identifying patients with NTM infections is limited diagnostic capacity (both clinical and laboratory) in many low and middle-income countries. The presentation of NTM pulmonary disease is usually non-specific, with radiological findings and disease sequelae being similar to those of TB. Most patients with NTM disease therefore end up receiving therapy for TB or other common infections for months or years. Even if the culture report shows growth of NTM, it may be ignored as a contaminant, and the patient may not be properly assessed for NTM disease (Varma-Basil and Bose, 2019). Extrapulmonary infections are frequently nosocomial: surgical site infections including post-laparoscopic surgeries, implant infections, central line-associated bloodstream infections, acupuncture needle-related infections, pedicure-related infections, hydrotherapy-associated infections, etc. (Shakoor

et al., 2019). A mycobacterial aetiology is frequently not sought until the patient has failed the broadest of antibiotic coverage. When the infection is community-acquired, mycobacteria are much lower down the list of differentials unless there are concerted efforts to increase awareness, e.g., in the case of Buruli ulcer in Japan (Yotsu et al., 2012).

Mycobacterial culture or specific tests should be requested, and laboratories need to be equipped to identify mycobacteria beyond *Mycobacterium tuberculosis* complex (Varma-Basil and Bose, 2019). NTM are susceptible to harsh decontamination techniques and thus detection is difficult for fastidious species like *Mycobacterium haemophilum* and those NTM requiring incubation at 30 °C (e.g., *Mycobacterium marinum*) or 45 °C (e.g., *Mycobacterium xenopi*), as well as extremely slow-growing species (e.g., *M. ulcerans*) (Pfyffer, 2015).

The identification techniques, including commercial molecular systems that can identify clinically relevant mycobacteria, either directly in samples or from cultured isolates, have their own limitations: they are technically exacting, costly, and in cases have low accuracy (Pfyffer, 2015; Quan et al., 2018). Additionally, susceptibility testing is mostly limited to broth-based methods, which are difficult to perform and read. Furthermore, due to a paucity of data, clinical breakpoints for some drug–bug combinations are still not available (Clinical and Laboratory Standards Institute, 2018). More recently, another avenue being explored for clinical use is that of genotypic detection of resistance mutations (Huh et al., 2019).

Most importantly, maintaining tests to identify and report NTM is not cost-effective, especially where test volumes are low. Few centres in resource-limited settings therefore invest in such expertise, resulting in reduced access to reliable diagnostics.

Recognition of NTM as a global concern

According to recent studies, NTM disease is increasing in the developed world. A recent systematic review analysed 22 studies on NTM in North America, Europe, Asia, and Australasia reporting this trend (Brode et al., 2014; van der Werf et al., 2014). NTM lung disease appears to be more prevalent with older age, whereas NTM disease in children, HIV-infected patients, and the immunosuppressed is generally extrapulmonary with a predilection for lymphadenitis. Disseminated NTM disease is more likely in transplant patients or patients with a severe primary immunodeficiency, i.e., STAT1

Table 1
Clinical importance of common non-tuberculous mycobacteria (NTM).

NTM species	Comments
<i>Mycobacterium avium</i> – <i>intracellulare</i> complex (MAC)	Commonly found in most environments and became prominent during the HIV epidemics. Causes lymphadenitis and lung disease. Prevalence in the HIV population has been reduced dramatically by ART, but it can affect HIV non-infected people and elderly women (Lady Windermere syndrome). Frequently associated with piped water, likely to affect middle-aged or older men with COPD, and can cause a pulmonary disease similar to TB.
<i>Mycobacterium kansasii</i>	Frequently pathogenic and very challenging to treat, especially <i>M. abscessus</i> ssp. <i>abscessus</i> , given its resistance to macrolides; Other subspecies include <i>massiliense</i> and <i>bolletii</i> .
<i>Mycobacterium abscessus</i> group	Not generally considered a pathogen unless nosocomial.
<i>Mycobacterium fortuitum</i> group	Relatively rare, but is commonly associated with fish tanks and marine exposure, especially following skin breaks. Most likely manifestations are skin lesions, which may appear 2–4 weeks after exposure. A high index of suspicion and knowledge of occupational history and pets is required to make the diagnosis.
<i>Mycobacterium marinum</i>	Presents as a chronic skin infection and can be seen in, but is not limited to, Sub-Saharan Africa and the tropics. It is more prevalent following rains and flooding, frequently following trauma, and affects children/adolescents, producing painless nodules and ulcers due to the action of a toxin mycolactone. ^a
<i>Mycobacterium ulcerans</i>	Generally causes lymphadenitis in children.
<i>Mycobacterium scrofulaceum</i>	Commonly reported as a cause of pulmonary disease and as complicating infection in post-TB patients.
<i>Mycobacterium szulgai</i>	Does not always represent disease, but when it does, it can be very challenging to manage as it generally does not respond to treatment.
<i>Mycobacterium simiae</i>	

ART, antiretroviral therapy; COPD, chronic obstructive pulmonary disease; TB, tuberculosis.

^a Reference: Sarfo et al., 2016.

deficiency, interferon-gamma receptor deficit, or recipients of anti-tumour necrosis factor alpha (anti-TNF- α). CF patients are likely to be colonized with NTM and may develop NTM disease. NTM can cause rapidly progressing fibrocavitary pulmonary disease or disseminated disease in the immunocompromised. Localized manifestations may be skin and soft tissue infection from direct inoculation and lymphadenitis, typically cervical. Table 1 shows the niches and importance of some common NTM species seen in clinical practice.

NTM have recently been found to be putative causes of iatrogenic infections and outbreaks, and are now established as nosocomial pathogens (Desai and Hurtado, 2018). Outbreaks in CF patients have occurred, demonstrating the role of the environment in colonizing and infecting predisposed individuals (Martiniano et al., 2017), and these human-to-human transmission events have been proven as possible through whole genome sequencing (Bryant et al., 2013; Kapnadak et al., 2016). Therefore, efforts must be made to protect CF patients from the hospital environment, as well as to reduce the potential of spread of frequently drug-resistant nosocomial strains amongst patients; these include thorough cleaning between patients, environmental sampling, negative pressure rooms, and HEPA filters and UV lamps in

outpatient spaces (Shakoor et al., 2019). Recently, the contamination of heater-cooler units produced by a specific manufacturer was implicated in a global outbreak of *M. chimaera* in post heart valve surgery patients, causing surgical site infections and/or endocarditis, characterized by high mortality rates. New models of the machines have rectified the problem; however, the infection can remain latent for many years. It is difficult to diagnose and treat, and therefore the extent of the problem is likely to be underestimated (Hasse et al., 2020; Scriven et al., 2018).

NTM as an emerging problem in Pakistan, a high TB burden country

Rapid diagnostics have not only improved TB detection, but the massive roll-out of Xpert MT/RIF in high-burden countries has also unmasked NTM infections masquerading as acid-fast bacillus (AFB) smear-positive TB that has failed to respond to several courses of anti-tubercular therapy: treatment failure or reactivation (Javid et al., 2016; Tahseen et al., 2016; Velayati et al., 2015).

Data from the mycobacteriology section of the clinical laboratories of Aga Khan University (AKU), which is also the




Figure 1. Distribution of the common groups of non-tuberculous mycobacteria (NTM) isolated from pulmonary and extrapulmonary samples with NTM infections over the period 2012 to 2018, from the Microbiology Laboratory of Aga Khan University Hospital, Karachi, Pakistan.

Note: MAC, *Mycobacterium avium-intracellulare* complex; MK, *Mycobacterium kansasii*; SGM, slow-growing mycobacteria; MACG, *Mycobacterium abscessus-chelonae* group; MFG, *Mycobacterium fortuitum* group; RGM, rapidly growing mycobacteria; M. spp., *Mycobacterium* species; P, pulmonary infections; EP, extrapulmonary infections.

supranational reference TB laboratory, were analysed. The laboratory, situated in Karachi, receives specimens from most parts of the country through a network of specimen collection units; however, the data only represent a single laboratory experience from Pakistan. These showed a 7.7-fold increase in NTM infections, from 21 cases in 2012 to 163 in 2018 (Figure 1). The greatest increase in numbers was seen in pulmonary disease, contributing to 89.6% of the NTM cases, with most patients having a prior history of TB and evidence of bronchiectasis and fibrocystic changes in their lungs.

Extrapulmonary NTM infections are less common, but are increasingly recognized as important agents of nosocomial infections. Reports from Pakistan have already been published and a review of laboratory data from AKU revealed that 42% of extrapulmonary NTM infections were post-surgical, after caesarean section, laparoscopic surgeries, orthopaedic surgeries with and without implants, and mastectomies. The rates of these procedures are increasing in both the private and public sectors of developing countries like Pakistan, but the accompanying infection prevention strategies both during and after surgery are woefully inadequate (Shakoor et al., 2019). With a low index of suspicion and limited access to proper laboratory diagnosis, this documented rate of nosocomial NTM infections may very likely be an underestimate of the real situation.

As expected, with such different predisposing factors, the spectrum of NTM species causing pulmonary and extrapulmonary infections also differs. In our setting, a predominance of slow-growing mycobacteria, *Mycobacterium avium*–*intracellulare* complex (MAC) and *Mycobacterium kansasii*, was common in the group with pulmonary infections, but not in those with extrapulmonary disease. Rapidly growing mycobacteria (RGM), primarily from *Mycobacterium chelonae*/*Mycobacterium abscessus* group (MCAG) and *Mycobacterium fortuitum* group (MFG), while seen in both pulmonary and extrapulmonary infections, were associated with more than 80% of extrapulmonary NTM infections.

An earlier study evaluating the distribution of NTM species across Pakistan suggested geographical variation across different regions, every area having its own distribution spectrum (Ahmed et al., 2013). The differences were especially discernible between urban centres where access to bronchoscopy and more in-depth diagnostic efforts contribute to the detection of a larger number of NTM cases. The study further suggested clarithromycin as the mainstay of therapy for NTM infections in both slow-growing (SGM) and rapidly growing (RGM), with linezolid as a good alternative. Resistance to fluoroquinolones was, however, prevalent. Among injectable drugs, most RGMs were susceptible to amikacin, while limited imipenem activity was reported on isolates from Pakistan (Ahmed et al., 2013). The susceptibility profile suggested the use of antimicrobials in the area, nosocomial isolates being more resistant to injectables, but community-acquired isolates showing higher resistance to commonly used oral agents like fluoroquinolones.

Future directions

A low level of suspicion, limited knowledge, and paucity of specialized laboratories frequently lead to diagnostic delays. The median time to diagnosis may be as high as 2 years or longer. The delay frequently results in increased disease severity, and loss of functional capacity is not infrequent. The advent of molecular testing for TB is a surrogate test that allows the diagnosis of NTM through deduction in the case of AFB-positive, TB PCR-negative results. MALDI-TOF MS (matrix-assisted laser desorption/ionization time-of-flight mass spectrometry) and sequencing has further reduced the time to diagnosis of NTM infections and has improved our capacity for speciation. These new techniques enable outbreak

investigations to be performed with some certainty. Phenotypic sensitivities are important, especially in patients who have received macrolides as monotherapy for infective exacerbation of COPD or who have relapsed or non-responsive disease. Differentiating colonization from disease often requires more than one outpatient visit and several sputum samples or a bronchoscopy to isolate mycobacteria. In patients with a co-existing lung pathology, the NTM may be a relatively innocent bystander or be a co-infection in synergy with *Aspergillus* spp. or *Pseudomonas aeruginosa* (Geurts et al., 2019).

Simpler and more rapid tests would be ideal in making the diagnosis of NTM disease more quickly. However, the development of such tests is complicated by the large number of NTM species that can cause disease and by the criteria for disease, which require more than just the presence of the microorganism. As a result, NTM disease will require multiple diagnostic parameters, leading to delays and higher costs. More specific biomarkers to monitor the progress of treatment and test cure are lacking. The treatment of NTM remains lengthy, in many cases 18 months with a minimum 12 months after culture conversion in lung disease. In the future, more effective therapies, biomarkers, and/or imaging may help reduce the duration of treatment in a precise way.

Ethical approval

Not required.

Conflict of interest

None to declare.

Acknowledgements

This project is part of the activities of the Global Tuberculosis Network (GTN) and of the WHO Collaborating Centre for Tuberculosis and Lung Diseases, Tradate, ITA-80, 2017–2020-GBM/RC/LDA. This article is part of a supplement entitled *Commemorating World Tuberculosis Day March 24th, 2020: "IT'S TIME TO FIND, TREAT ALL and END TUBERCULOSIS!"* published with support from an unrestricted educational grant from QIAGEN Sciences Inc.

References

- Ahmed I, Jabeen K, Hasan R. Identification of non-tuberculous mycobacteria isolated from clinical specimens at a tertiary care hospital: a cross-sectional study. *BMC Infect Dis* 2013;13:493.
- Brode SK, Daley CL, Marras TK. The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: a systematic review. *Int J Tuberc Lung Dis* 2014;18(11):1370–7.
- Bryant JM, Grogono DM, Greaves D, Foweraker J, Roddick I, Inns T, et al. Whole-genome sequencing to identify transmission of *Mycobacterium abscessus* between patients with cystic fibrosis: a retrospective cohort study. *Lancet* 2013;381(9877):1551–60.
- Buser GL, Laidler MR, Cassidy PM, Moulton-Meissner H, Beldavs ZG, Cieslak PR. Outbreak of nontuberculous mycobacteria joint prosthesis infections, Oregon, USA, 2010–2016. *Emerg Infect Dis* 2019;25(5):849–55.
- Clinical and Laboratory Standards Institute. Performance standards for susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes. M62. 1st ed. Clinical and Laboratory Standards Institute; 2018.
- Desai AN, Hurtado RM. Infections and outbreaks of nontuberculous mycobacteria in hospital settings. *Curr Treat Options Infect Dis* 2018;10(2):169–81.
- Esteban J, Garcia-Coca M. *Mycobacterium* biofilms. *Front Microbiol* 2017;8:2651.
- Faverio P, Stainer A, Bonaiti G, Zucchetti SC, Simonetta E, Lapadula G, et al. Characterizing non-tuberculous mycobacteria infection in bronchiectasis. *Int J Mol Sci* 2016;17(11).
- Forbes BA. Mycobacterial taxonomy. *J Clin Microbiol* 2017;55(2):380–3.
- Geurts K, Zweijpfenning SMH, Pennings LJ, Schildkraut JA, Boeree MJ, Magis-Escarra C, et al. Nontuberculous mycobacterial pulmonary disease and aspergillus co-infection: Bonnie and Clyde? *Eur Respir J* 2019;54(1).

- Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med* 2007;175(4):367–416.
- Hasse B, Hannan M, Keller PM, Maurer FP, Sommerstein R, Mertz D, et al. International society of cardiovascular infectious diseases guidelines for the diagnosis, treatment and prevention of disseminated *Mycobacterium chimaera* infection following cardiac surgery with cardiopulmonary bypass. *J Hosp Infect* 2020;104(2):214–35.
- Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. *Eur Respir J* 2013;42(6):1604–13.
- Honda JR, Virdi R, Chan ED. Global environmental nontuberculous mycobacteria and their contemporaneous man-made and natural niches. *Front Microbiol* 2018;9:2029.
- Huh HJ, Kim SY, Shim HJ, Kim DH, Yoo IY, Kang OK, et al. GenoType NTM-DR performance evaluation for identification of *Mycobacterium avium* complex and *Mycobacterium abscessus* and determination of clarithromycin and amikacin resistance. *J Clin Microbiol* 2019;57(8).
- Javadi M, Ahmed A, Asif S, Raza A. Diagnostic plausibility of MTBDRplus and MTBDRsl line probe assays for rapid drug susceptibility testing of drug resistant *Mycobacterium tuberculosis* strains in Pakistan. *Int J Infect* 2016;3(3):e34903.
- Kapnadak SG, Hisert KB, Pottinger PS, Limaye AP, Aitken ML. Infection control strategies that successfully controlled an outbreak of *Mycobacterium abscessus* at a cystic fibrosis center. *Am J Infect Control* 2016;44(2):154–9.
- Lyman MM, Grigg C, Kinsey CB, Keckler MS, Moulton-Meissner H, Cooper E, et al. Invasive nontuberculous mycobacterial infections among cardiothoracic surgical patients exposed to heater-cooler devices(1). *Emerg Infect Dis* 2017;23(5):796–805.
- Martiniano SL, Davidson RM, Nick JA. Nontuberculous mycobacteria in cystic fibrosis: updates and the path forward. *Pediatr Pulmonol* 2017;52(S48):S29–36.
- Pfyffer GE. *Mycobacterium*: general characteristics, laboratory detection, and staining procedures. In: Jorgensen JH, Pfaller MA, Carroll KC, Funke G, Landry ML, Richter SS, Warnock DW, editors. *Manual of clinical microbiology*. 11 ed. Washington, DC: ASM Press; 2015.
- Prevots DR, Loddenkemper R, Sotgiu G, Migliori GB. Nontuberculous mycobacterial pulmonary disease: an increasing burden with substantial costs. *Eur Respir J* 2017;49(4).
- Quan TP, Bawa Z, Foster D, Walker T, Del Ojo Elias C, Rathod P, et al. Evaluation of whole-genome sequencing for mycobacterial species identification and drug susceptibility testing in a clinical setting: a large-scale prospective assessment of performance against line probe assays and phenotyping. *J Clin Microbiol* 2018;56(2).
- Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of *Mycobacterium ulcerans* infection/Buruli ulcer disease. *Cell Microbiol* 2016;18(1):17–29.
- Scriven JE, Scobie A, Verlander NQ, Houston A, Collins T, Cajic V, et al. *Mycobacterium chimaera* infection following cardiac surgery in the United Kingdom: clinical features and outcome of the first 30 cases. *Clin Microbiol Infect* 2018;24(11):1164–70.
- Shah NM, Davidson JA, Anderson LF, Lalor MK, Kim J, Thomas HL, et al. Pulmonary *Mycobacterium avium*-intracellulare is the main driver of the rise in nontuberculous mycobacteria incidence in England, Wales and Northern Ireland, 2007–2012. *BMC Infect Dis* 2016;16:195.
- Shakoor S, Owais M, Hasan R, Irfan Seema. Nosocomial and healthcare-associated NTM infections and their control. In: Velayati AA, Farnia P, editors. *Nontuberculous mycobacteria (NTM) microbiological, clinical and geographical distribution*. Elsevier Inc.; 2019. p. 177–90.
- Tahseen S, Qadeer E, Khanzada FM, Rizvi AH, Dean A, Van Deun A, et al. Use of Xpert ((R)) MTB/RIF assay in the first national anti-tuberculosis drug resistance survey in Pakistan. *Int J Tuberc Lung Dis* 2016;20(4):448–55.
- van der Werf MJ, Kodmon C, Katalinic-Jankovic V, Kummik T, Soini H, Richter E, et al. Inventory study of non-tuberculous mycobacteria in the European Union. *BMC Infect Dis* 2014;14:62.
- Varma-Basil M, Bose M. Mapping the footprints of nontuberculous mycobacteria: a diagnostic dilemma. In: Velayati AA, Farina P, editors. *Nontuberculous mycobacteria (NTM) microbiological, clinical and geographical distribution*. . p. 155–75.
- Velayati AA, Rahideh S, Nezhad ZD, Farnia P, Mirsaeidi M. Nontuberculous mycobacteria in Middle East: current situation and future challenges. *Int J Mycobacteriol* 2015;4(1):7–17.
- Yotsu RR, Nakanaga K, Hoshino Y, Suzuki K, Ishii N. Buruli ulcer and current situation in Japan: a new emerging cutaneous *Mycobacterium* infection. *J Dermatol* 2012;39(7):587–93.